Results 101 to 110 of about 901 (171)

Differential Influence of the Antiretroviral Pharmacokinetic Enhancers Ritonavir and Cobicistat on Intestinal P-Glycoprotein Transport and the Pharmacokinetic/Pharmacodynamic Disposition of Dabigatran

open access: yes, 2017
Dabigatran etexilate (DE) is a P-glycoprotein (P-gp) probe substrate, and its active anticoagulant moiety, dabigatran, is a substrate of the multidrug and toxin extrusion protein-1 (MATE-1) transporter.
Parag Kumar   +10 more
core   +1 more source

Switch to bictegravir/emtricitabine/tenofovir alafenamide in people living with HIV aged 65 years or older: BICOLDER study – IMEA 057

open access: yesJournal of Infection and Public Health
Background: Polymedication and comorbidities are frequent in aging people with HIV (PWH) and often associated with elevated incidences of adverse events (AEs) and drug-drug interactions (DDIs).
Minh P. Lê   +12 more
doaj   +1 more source

Elvitegravir/cobicistat-associated toxic optical neuropathy in an HIV-infected patient: a call for caution?

open access: yes, 2017
Ocular toxicity may not only be caused by medication overdoses and drug-drug interactions, but also by the chronic administration of medications at recommended doses.
A. Invernizzi   +5 more
core   +1 more source

Concentration-time profiles for the accumulation of elvitegravir in U1 cells with or without cobicistat and ethanol.

open access: yes, 2017
Results expressed as means ± SEM of the cellular concentrations measured (μM/mg of protein). EVG, Elvitegravir; COBI, Cobicistat; EtOH, ethanol.
Pradeep B. Lukka (3775327)   +4 more
core   +1 more source

Synergistic antifungal activity of antiretrovirals with amphotericin B against Aspergillus species.

open access: yesPLoS ONE
Aspergillosis is a life-threatening fungal infection that primarily affects the lungs of immunocompromised individuals, including those living with human immunodeficiency virus (HIV), and is associated with mortality rates exceeding 50%. The infection is
Ammar A Khan   +2 more
doaj   +1 more source

Profile of once-daily darunavir/cobicistat fixed-dose combination for the treatment of HIV/AIDS

open access: yes
Altres ajuts: AC has received honoraria, speakers' fees and/or funds for research from Bristol-Myers Squibb, Abbvie, Gilead Sciences, Janssen-Cilag, MSD, and ViiV Healthcare. JN has received honoraria, speakers' fees and/or funds for research from Abbvie,
Curran, Adrian   +2 more
core  

Kinetic Characterization of elvitegravir (EVG) in the presence and absence of cobicistat (COBI) and/or ethanol (EtOH)

open access: yes, 2016
Kinetic Characterization of elvitegravir (EVG) in the presence and absence of cobicistat (COBI) and/or ethanol (EtOH)
Mohammad A. Rahman (1806823)   +6 more
core  

UPLC SEPARATION ANALYSIS OF EMTRICITABINE, TENOFOVIR, COBICISTAT AND ELVITEGRAVIR FROM THEIR DEGRADATION PRODUCTS

open access: yes, 2016
Objective: A simple, rapid, accurate and precise stability-indicating UPLC analytical method has been developed and validated for the quantitative analysis of Emtricitabine, Tenofovir, Cobicistat and Elvitegravir in bulk drugs and combined dosage forms ...
P., Prahlad   +4 more
core  

Home - About - Disclaimer - Privacy